In this section, you can review LDL cholesterol reduction results and LDL cholesterol goal attainment results from
comparative clinical trials in which CRESTOR® (rosuvastatin calcium) was used as an adjunct to diet in
patients starting statin therapy. You can also download the STELLAR publication.
LDL Cholesterol Reductions vs Other Statins
-
LDL-C reductions vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis
-
-
LDL-C reductions vs atorvastatin in patients with cardiovascular disease (CVD) and low HDL-C
-
-
LDL-C reductions vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia
-
-
LDL-C reductions vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia
-
-
LDL-C reductions vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia
-
LDL Cholesterol Goal Attainment vs Other Statins
-
NCEP ATP III Guideline Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis
-
-
Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia
-
-
Goal attainment (LDL-C <100 mg/dL) vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia
-
-
Goal attainment (LDL-C <100 mg/dL) vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia
-
LDL-C reductions vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis
*P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg;
CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.
Mean baseline LDL-C: 188 mg/dL to 189 mg/dL (all arms of trial).
Week 6:
CRESTOR 10 mg n=498
atorvastatin 10 mg n=510
Week 12:
CRESTOR 20 mg n=492
atorvastatin 20 mg n=494
Week 18:
CRESTOR 40 mg n=480
atorvastatin 40 mg n=483
Week 24:
CRESTOR 40 mg n=464
atorvastatin 80 mg n=476
ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in patients with hypercholesterolemia and CHD, CHD risk equivalents (10-year risk >20%), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 24. Percentage change from baseline in HDL-C was a secondary end point.
LDL-C reductions vs atorvastatin in patients with cardiovascular disease (CVD) and low HDL-C
*P<.05 CRESTOR 10 mg vs atorvastatin 20 mg.
†P<.01 CRESTOR 20 mg vs atorvastatin 40 mg.
‡P<.0001 CRESTOR 40 mg vs atorvastatin 80 mg.
Mean baseline LDL-C: 139 mg/dL to 143 mg/dL.
CRESTOR n=230
atorvastatin n=231
RADAR was a randomized, multicenter, open-label, parallel-group,
forced-titration trial comparing the efficacy and safety of
CRESTOR with atorvastatin in hypercholesterolemic patients
with CVD and low HDL-C levels (<40 mg/dL). Patients were
randomized to receive CRESTOR 10 mg or atorvastatin 20 mg for
6 weeks. At week 6, doses were increased to CRESTOR 20 mg or
atorvastatin 40 mg, and at week 12, doses were increased to
CRESTOR 40 mg or atorvastatin 80 mg for a further 6 weeks.
Statistical comparisons were not made across the dose range,
only across the same time period (6 weeks vs 6 weeks, 12 weeks
vs 12 weeks, 18 weeks vs 18 weeks). The primary end point of
RADAR was the percentage change from baseline in LDL-C/HDL-C
ratio at 6 weeks.
LDL-C reductions vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia
*P<.002 CRESTOR 10 mg vs atorvastatin 10 mg.
†P<.002 CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg.
‡P<.002 CRESTOR 40 mg vs atorvastatin 40 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).
CRESTOR n=473
atorvastatin n=634
STELLAR was a 6-week, multicenter, open-label, randomized,
15-arm trial comparing the efficacy and safety of CRESTOR with
atorvastatin, simvastatin, and pravastatin in 2240 patients with
hyperlipidemia or mixed dyslipidemia. The primary end point was percentage
change from baseline in LDL-C at week 6. The study performed the
following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg,
20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and
pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs
atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg,
and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs
atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and
pravastatin 40 mg.
LDL-C reductions vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia
*P<.002 CRESTOR 10 mg vs simvastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs simvastatin 20 mg, 40 mg, 80 mg.
‡P<.002 CRESTOR 40 mg vs simvastatin 40 mg, 80 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).
CRESTOR n=473
simvastatin n=648
STELLAR was a 6-week, multicenter, open-label, randomized,
15-arm trial comparing the efficacy and safety of CRESTOR with
atorvastatin, simvastatin, and pravastatin in 2240 patients with
hyperlipidemia or mixed dyslipidemia. The primary end point was
percentage change from baseline in LDL-C at week 6. The study
performed the following dose comparisons: CRESTOR 10 mg vs
atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg,
and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg
vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg,
40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR
40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and
80 mg, and pravastatin 40 mg.
LDL-C reductions vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia
*P<.002 CRESTOR 10 mg vs pravastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs pravastatin 20 mg, 40 mg.
‡P<.002 CRESTOR 40 mg vs pravastatin 40 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).
CRESTOR n=473
pravastatin n=485
STELLAR was a 6-week, multicenter, open-label, randomized,
15-arm trial comparing the efficacy and safety of CRESTOR with
atorvastatin, simvastatin, and pravastatin in 2240 patients with
hyperlipidemia or mixed dyslipidemia. The primary end point was
percentage change from baseline in LDL-C at week 6. The study
performed the following dose comparisons: CRESTOR 10 mg vs
atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg,
and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg
vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg,
40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR
40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and
80 mg, and pravastatin 40 mg.
NCEP ATP III Guideline Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis
†P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.
Mean baseline LDL-C: 188 mg/dL to 189 mg/dL (all arms of trial).
Week 6:
CRESTOR 10 mg n=498
atorvastatin 10 mg n=510
Week 12:
CRESTOR 20 mg n=492
atorvastatin 20 mg n=494
Week 18:
CRESTOR 40 mg n=480
atorvastatin 40 mg n=483
Week 24:
CRESTOR 40 mg n=464
atorvastatin 80 mg n=476
According to the NCEP ATP III Guidelines, the LDL-C goal for 0 to 1 risk factors is <160 mg/dL, 2+ risk factors (10-year risk <20%) is <130 mg/dL, and CHD or CHD risk equivalents (10-year risk >20%) is <100 mg/dL.
ECLIPSE was a 24-week, open-label, randomized, multicenter,
forced-titration, parallel-group trial comparing the efficacy
and safety of CRESTOR and atorvastatin in patients with
hypercholesterolemia and CHD, CHD risk equivalents (10-year
risk >20%), or clinical evidence of atherosclerosis.
Following a 6-week dietary lead-in period, patients were
randomized to receive CRESTOR 10 mg or atorvastatin 10 mg
for 6 weeks. Doses were force-titrated at 6-week intervals
until maximum doses were achieved. Statistical comparisons
were not made across the dose range, only across the same
time period. The primary end point was percentage of patients
achieving NCEP ATP III LDL-C goal at week 24. Percentage
change from baseline in HDL-C was a secondary end point.
Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia
*P<.002 CRESTOR 10 mg vs atorvastatin 10 mg.
†P<.002 CRESTOR 20 mg vs atorvastatin 20 mg.
‡P<.002 CRESTOR 40 mg vs atorvastatin 40 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL
CRESTOR 10 mg n=156
CRESTOR 20 mg n=160
CRESTOR 40 mg n=157
atorvastatin 10 mg n=158
atorvastatin 20 mg n=154
atorvastatin 40 mg n=156
atorvastatin 80 mg n=165
STELLAR was a 6-week, multicenter, open-label, randomized,
15-arm trial comparing the efficacy and safety of CRESTOR
with atorvastatin, simvastatin, and pravastatin in 2240
patients with hyperlipidemia or mixed dyslipidemia. The primary end
point was percentage change from baseline in LDL-C at week
6. The study performed the following dose comparisons:
CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg,
simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg,
20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg,
and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and
pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs
atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and
pravastatin 40 mg.
Goal attainment (LDL-C <100 mg/dL) vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia
*P<.002 CRESTOR 10 mg vs simvastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs simvastatin 20 mg, 40 mg, 80 mg.
‡P<.002 CRESTOR 40 mg vs simvastatin 40 mg, 80 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).
CRESTOR 10 mg n=156
CRESTOR 20 mg n=160
CRESTOR 40 mg n=157
simvastatin 10 mg n=165
simvastatin 20 mg n=162
simvastatin 40 mg n=158
simvastatin 80 mg n=163
STELLAR was a 6-week, multicenter, open-label, randomized,
15-arm trial comparing the efficacy and safety of CRESTOR with
atorvastatin, simvastatin, and pravastatin in 2240 patients with
hyperlipidemia or mixed dyslipidemia. The primary end point was percentage
change from baseline in LDL-C at week 6. The study performed the
following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg,
20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and
pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin
20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg,
and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin
40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.
Goal attainment (LDL-C <100 mg/dL) vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia
*P<.002 CRESTOR 10 mg vs pravastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs pravastatin 20 mg, 40 mg.
‡P<.002 CRESTOR 40 mg vs pravastatin 40 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).
CRESTOR 10 mg n=156
CRESTOR 20 mg n=160
CRESTOR 40 mg n=157
pravastatin 10 mg n=160
pravastatin 20 mg n=164
pravastatin 40 mg n=161
STELLAR was a 6-week, multicenter, open-label, randomized,
15-arm trial comparing the efficacy and safety of CRESTOR with
atorvastatin, simvastatin, and pravastatin in 2240 patients with
hyperlipidemia or mixed dyslipidemia. The primary end point was percentage
change from baseline in LDL-C at week 6. The study performed the
following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg,
20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and
pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin
20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg,
and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin
40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.